Home › Compare › BRIBF vs JNJ

BRIBF vs JNJ: Dividend Comparison 2026

BRIBF yields 1062.70% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084463.98M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — BRIBF vs JNJ

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BRIBF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, BRIBF beats the other by $23,012,056,878,733.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + JNJ for your $10,000?

BRIBF: 50%JNJ: 50%
100% JNJ50/50100% BRIBF
Portfolio after 10yr
$16042232.01M
Annual income
$13,536,504,047,141.32/yr
Blended yield
84.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BRIBF
No analyst data
Altman Z
19.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
JNJ buys
0
No recent congressional trades found for BRIBF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFJNJ
Forward yield1062.70% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$32084464.00M ✓$20.0K
Annual income after 10y$27,073,008,093,454.87 ✓$827.78
Total dividends collected$31704729.30M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BRIBF vs JNJ ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$116,970$106,269.93$10,676$355.77+$106.3K → BRIBF
2$1,286,876$1,161,718.25$11,407$389.39+$1.28M → BRIBF
3$13,321,776$11,944,818.28$12,198$426.53+$13.31M → BRIBF
4$129,817,926$115,563,625.92$13,056$467.62+$129.80M → BRIBF
5$1,191,375,681$1,052,470,500.56$13,987$513.12+$1191.36M → BRIBF
6$10,301,704,979$9,026,933,000.21$14,998$563.56+$10301.69M → BRIBF
7$83,971,400,363$72,948,576,035.34$16,098$619.52+$83971.38M → BRIBF
8$645,568,504,677$555,719,106,288.88$17,295$681.69+$645568.49M → BRIBF
9$4,683,603,649,023$3,992,845,349,018.69$18,599$750.82+$4683603.63M → BRIBF
10$32,084,463,997,910$27,073,008,093,454.87$20,022$827.78+$32084463.98M → BRIBF

BRIBF vs JNJ: Complete Analysis 2026

BRIBF — Stock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this BRIBF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs JEPIBRIBF vs OBRIBF vs KOBRIBF vs MAINBRIBF vs ABBVBRIBF vs MRKBRIBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.